Skip to main
CING
CING logo

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. has demonstrated a strong capacity for innovation with its proprietary precision timed-release drug delivery platform, particularly through its ADHD treatment, CTx-1301, which has shown clinically significant improvements in the Permanent Product Measure of Performance (PERMP) with an impressive average effect size of 1.79, surpassing that of existing competitor drugs. The consistent enhancements in PERMP scores observed from just 30 minutes to 16 hours indicate the potential of CTx-1301 to reshape the ADHD treatment landscape. Furthermore, the company has strengthened its balance sheet and increased its probability of approval for CTx-1301 to 75%, indicating a robust pipeline and favorable outlook for future product candidates.

Bears say

Cingulate Inc. has significantly underperformed relative to the biotech sector, largely due to dilutive equity financings and slower-than-expected progress in its drug development pipeline. The company's stock has declined approximately 95% year-to-date, influenced by concerns over patient outcomes, challenges in market uptake of CTx-1301, and potential revenue erosion from complex patent procedures anticipated to begin in 2036. Additionally, risks associated with NDA filing delays, reliance on partnerships, and the possibility of failure in ongoing clinical studies contribute to a negative outlook for the company's financial future.

Cingulate (CING) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jul 2, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.79, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.79, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.